GlassScriptPhysician profile
Joseph L Carr
NPI 1285339721
$2,442.13
in general payments reported to CMS, 2019-2025
21 companies · $965 in 2025
The $965 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $752 · 2024: $725 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407 · Education: $34.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.27 |
| Education | $34.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.43 | 2024-2025 | |
| Axsome Therapeutics, INC. | $261.19 | 2023 | Sunosi |
| Jazz Pharmaceuticals INC. | $211.01 | 2023 | |
| Janssen Biotech, INC. | $204.05 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.55 | 2024-2025 | Xifaxan, Trulance, Plenvu |
| Ferring Pharmaceuticals INC. | $181.96 | 2023-2025 | Rebyota |
| Celltrion USA INC. | $160.36 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $155.71 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $114.38 | 2024-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $81.25 | 2024-2025 | Dupixent |
| Pfizer INC. | $75.60 | 2024-2025 | |
| Inspire Medical Systems, INC. | $68.27 | 2023 | Inspire |
| Aimmune Therapeutics, INC. | $56.41 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $45.89 | 2024 | |
| Zoll Respicardia, INC. | $45.07 | 2023-2025 | Remede System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.55 | 2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $31.86 | 2023-2024 | Voquezna |
| Organon LLC | $30.82 | 2024-2025 | Hadlima, Renflexis |
| Fisher & Paykel Healthcare INC | $25.64 | 2023 | Fisher & Paykel Healthcare |
| Genzyme Corporation | $15.97 | 2024 | |
| Harmony Biosciences LLC | $15.16 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.